Journals / The Anatolian Journal of Cardiology / 2017 / Cilt: 17 - Sayı: 2

Treatment-associated change in apelin concentration in patients with hypertension and its relationship with left ventricular diastolic function

Pages
125–131
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Change in apelin concentration was not associated with improvement in diastolic function

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We examined the change in apelin concentration and its relationship with left ventricular diastolic function in patients treated for hypertension.Methods: Ninety treatment-naive patients with newly diagnosed hypertension and 33 age- and sex-matched control subjects were prospectively enrolled.
📊
Key Findings & Data:Patients with hypertension were randomized to treatment either with telmisartan 80 mg or amlodipine 10 mg.
💡
Conclusion & Impact:Change in apelin concentration was not associated with improvement in diastolic function
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We examined the change in apelin concentration and its relationship with left ventricular diastolic function in patients treated for hypertension.Methods: Ninety treatment-naive patients with newly diagnosed hypertension and 33 age- and sex-matched control subjects were prospectively enrolled. Patients with hypertension were randomized to treatment either with telmisartan 80 mg or amlodipine 10 mg. Apelin concentration was measured and echocardiography was performed at baseline and after 1 month of treatment.Results: The data of 77 patients and 33 controls were analyzed. Mean age, gender, baseline blood pressure, apelin levels, and echocardiographic measurements were similar between the treatment groups (p>0.05 for all). Apelin concentration was significantly lower in patients with hypertension than in controls. There was a significant increase in apelin level after 1 month of treatment in both groups (0.32±0.17 vs. 0.38±0.17 ng/dL in telmisartan group, p=0.009, and 0.27±0.13 vs. 0.34±0.18 ng/dL in amlodipine group, p=0.013). Diastolic function improved significantly in both groups (p<0.05) but was not significantly associated with change in apelin concentration.Conclusion: Apelin concentration increased significantly after 1 month of effective treatment with telmisartan or amlodipine to a similar extent. Change in apelin concentration was not associated with improvement in diastolic function

🔖

Cite This Article

BAYSAL, S. S., PİRAT, B., OKYAY, K., BAL, U. A., ULUÇAM, M. Z., ÖZTUNA, D., MÜDERRİSOĞLU, H. (2017). Treatment-associated change in apelin concentration in patients with hypertension and its relationship with left ventricular diastolic function. The Anatolian Journal of Cardiology, Cilt: 17 - Sayı: 2, 125–131. https://ajindex.com/articles/366717

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakewaga T, Zou MX. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251: 471-6
  2. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000; 74: 34-41
  3. Barnes G, Japp AG, Newby DE. Translational promise of the apelin/ APJ system. Heart 2010; 96: 1011-6
  4. Sönmez A, Çelebi G, Erdem G, Tapan S, Genç H, Taşcı I, et al. Plasma apelin and ADMA levels in patients with essential hypertension. Clin Exp Hypertens 2010; 32: 179-83
  5. Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens 2011; 29: 971-9
  6. Charles CJ. Putative role for apelin in pressure/volume homeostasis and cardiovascular disease. Cardiovasc Hematol Agents Med Chem 2007; 5: 1-10
  7. Mancia G, Fagard R, Narkiewicz K, Redán J, Zanchetti A, Böhm M, et al. 2013 Practice guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 34: 1925-38
  8. Zhou Y, Wang Y, Qiao S. Apelin: a potential marker of coronary artery stenosis and atherosclerotic plaque stability in ACS patients. Int Heart J 2014; 55: 204-12
  9. Cebeci AN, Güven A, Kuru LI. Perinephric adipose tissue thickness in relation to blood pressure, plasma apelin and C -reactive protein levels in obese adolescents. Minerva Endocrinol 2016; 41: 166-74
  10. Habchi M, Duvillard L, Cottet V, Brindisi MC, Bouillet B, Beacco M, et al. Circulating apelin is increased in patients with type 1 or type 2 diabetes and is associated with better glycaemic control. Clin Endocrinol (Oxf) 2014; 81: 696-701
  11. Peltonen T, Näpänkangas J, Vuolteenaho O, Ohtonen P, Soini Y, Juvonen T, et al. Apelin and its receptor APJ in human aortic valve stenosis. J Heart Valve Dis 2009; 18: 644-52
  12. Zhang DL, Liao H, Wei YY, Zhang Y, Zhang QD, Wang ZG. Elevation of serum apelin-13 is positively correlated with ADMA in patients on maintenance hemodialysis. Clin Nephrol 2009; 71: 405-12
  13. Dalzell JR, Rocchiccioli JP, Weir RA, Jackson CE, Padmanabhan N, Gardner RS, et al. The Emerging Potential of the Apelin-APJ System in Heart Failure. J Card Fail 2015; 21: 489-98
  14. Chapman CB, Ewer SM, Kelly A